NEAL KLEIMAN to Dose-Response Relationship, Drug
This is a "connection" page, showing publications NEAL KLEIMAN has written about Dose-Response Relationship, Drug.
Connection Strength
0.248
-
Searching for the ceiling: new reflections on the disposition and metabolism of clopidogrel. JACC Cardiovasc Interv. 2008 Dec; 1(6):628-30.
Score: 0.047
-
Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. Thromb Haemost. 2008 Jul; 100(1):83-9.
Score: 0.045
-
Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res. 2007; 119(3):355-60.
Score: 0.039
-
Could clopidogrel's platelet inhibition be enhanced by an increased loading dose and eptifibatide? Nat Clin Pract Cardiovasc Med. 2005 Jul; 2(7):344-5.
Score: 0.037
-
Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction". Am Heart J. 2011 Jul; 162(1):89-97.
Score: 0.014
-
Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. J Am Coll Cardiol. 2010 Jan 12; 55(2):114-21.
Score: 0.013
-
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation. 2008 Feb 19; 117(7):886-96.
Score: 0.011
-
Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial. J Gen Intern Med. 2008 Mar; 23(3):310-6.
Score: 0.011
-
Effect of P-selectin on phosphatidylserine exposure and surface-dependent thrombin generation on monocytes. Arterioscler Thromb Vasc Biol. 2005 May; 25(5):1065-70.
Score: 0.009
-
Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol. 2004 May 01; 93(9):1092-6.
Score: 0.008
-
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation. 2002 May 21; 105(20):2385-91.
Score: 0.007
-
Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation. 2002 Feb 19; 105(7):788-93.
Score: 0.007